Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Clapham

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|October 6, 2019
Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?John C Clapham
Idrugs : the Investigational Drugs Journal|March 11, 2004
Fat oxidation in obesity: druggable or risky enterprise?John C Clapham
Neuropharmacology|November 9, 2011
Central control of thermogenesisJohn C Clapham
Current Drug Targets|April 3, 2004
Treating obesity: pharmacology of energy expenditureJohn C Clapham
Expert Opinion on Drug Discovery|March 15, 2013
Cell based in vitro and ex vivo models in metabolic disease drug discovery: nice to have or critical path?Stefan Hallén, John C Clapham
European Journal of Pharmacology|November 4, 2006
Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing?Peter J Greasley, John C Clapham
Expert Opinion on Therapeutic Targets|September 20, 2006
The fatty acid oxidation pathway as a therapeutic target for insulin resistanceJohn C Clapham, Leonard H Storlien
Pharmacology & Therapeutics|April 26, 2011
Targeting thermogenesis and related pathways in anti-obesity drug discoveryJohn C Clapham, Jonathan R S Arch
Annals of the New York Academy of Sciences|June 25, 2002
Enhanced diabetogenic effect of streptozotocin in mice overexpressing UCP-3 in skeletal muscleSteven Wang, Michael A Cawthorne, John C Clapham
Biochimica Et Biophysica Acta|September 29, 2004
Glucose and fatty acid metabolism in McA-RH7777 hepatoma cells vs. rat primary hepatocytes: responsiveness to nutrient availabilityPia K Hansson, Anna-Karin Asztély, John C Clapham, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|October 6, 2019
Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?John C Clapham
Idrugs : the Investigational Drugs Journal|March 11, 2004
Fat oxidation in obesity: druggable or risky enterprise?John C Clapham
Neuropharmacology|November 9, 2011
Central control of thermogenesisJohn C Clapham
Current Drug Targets|April 3, 2004
Treating obesity: pharmacology of energy expenditureJohn C Clapham
Expert Opinion on Drug Discovery|March 15, 2013
Cell based in vitro and ex vivo models in metabolic disease drug discovery: nice to have or critical path?Stefan Hallén, John C Clapham
European Journal of Pharmacology|November 4, 2006
Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing?Peter J Greasley, John C Clapham
Expert Opinion on Therapeutic Targets|September 20, 2006
The fatty acid oxidation pathway as a therapeutic target for insulin resistanceJohn C Clapham, Leonard H Storlien
Pharmacology & Therapeutics|April 26, 2011
Targeting thermogenesis and related pathways in anti-obesity drug discoveryJohn C Clapham, Jonathan R S Arch
Annals of the New York Academy of Sciences|June 25, 2002
Enhanced diabetogenic effect of streptozotocin in mice overexpressing UCP-3 in skeletal muscleSteven Wang, Michael A Cawthorne, John C Clapham
Biochimica Et Biophysica Acta|September 29, 2004
Glucose and fatty acid metabolism in McA-RH7777 hepatoma cells vs. rat primary hepatocytes: responsiveness to nutrient availabilityPia K Hansson, Anna-Karin Asztély, John C Clapham, et al.
Pageof 3